Electron Pushing: Variants That Alter the Catalytic Distribution of Electrons in Dihydroorotate Dehydrogenase 1B from .

Biochemistry

Loyola University Chicago, Department of Chemistry and Biochemistry, 1068 W Sheridan Rd, Chicago, Illinois 60660, United States.

Published: September 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Dihydroorotate dehydrogenase 1B (DHOD1B) is one of several flavoproteins that utilize active half-sites. These enzymes have two flavin cofactors (FAD and FMN) that each interact with a specific reductant/oxidant substrate/product. Electrons gained at one-half-site must be transmitted to the other half-site and iron-sulfur centers between the flavin cofactors serve in this role. DHOD1B from (LlDHOD1B) is a heterodimeric protein that has been shown to fractionally accumulate a flavin bisemiquinone state comprised of equimolar anionic and neutral forms, demonstrating an internal electron distribution equilibrium. Variant forms of LlDHOD1B were designed to perturb predicted or claimed pathways for internal transmission of electrons. Lysine 48 of the PyrD subunit is positioned near the FMN isoalloxazine N5 and the orotate C6-carboxylate. The K48M variant revealed that the anionic semiquinone resides at the FMN cofactor and that the lysine's role is electrostatic, influencing both the p and reduction potential of the FMN. Glutamate 221 of the PyrK subunit stacks with the FAD isoalloxazine. The E221Q variant established that this charge influences the rate of hydride transfer from NADH and the rate of reduction of orotate and accumulates little of the flavin bisemiquinone observed with the WT enzyme. Cysteine 135 of the PyrD subunit serves as the active half-site acid/base. The C135A variant prevented reduction of orotate, permitting the influence of orotate binding on the reduction potential of the FMN cofactor to be determined indicating a +70 mV change in the FMN reduction potential with the association of orotate.

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.biochem.5c00409DOI Listing

Publication Analysis

Top Keywords

reduction potential
12
dihydroorotate dehydrogenase
8
flavin cofactors
8
flavin bisemiquinone
8
pyrd subunit
8
fmn cofactor
8
potential fmn
8
reduction orotate
8
fmn
6
orotate
5

Similar Publications

Purpose: To evaluate the efficacy and underlying mechanism of advanced optimal pulse technology intense pulsed light (AOPT) in low-energy triple-pulse long-width mode (AOPT-LTL) for melasma treatment.

Methods: An in vivo guinea pig model of melasma was established through progesterone injection and ultraviolet B radiation. Three sessions of AOPT-LTL treatment were performed weekly.

View Article and Find Full Text PDF

: The therapeutic potential of vegetarian diets in metabolic dysfunction-associated steatotic liver disease (MASLD) remains understudied in Asian populations. This randomized controlled trial aimed to evaluate the effects of a culturally adapted 6-month lacto-ovo-vegetarian diet (LOV-D) on hepatic steatosis and cardiometabolic risk factors through weight loss. : In this randomized trial, 220 Chinese adults with MASLD were assigned to LOV-D ( = 110) or an omnivore diet ( = 110) for 6 months.

View Article and Find Full Text PDF

Developing efficient, low-cost catalysts for oxygen reduction and evolution reactions (ORR and OER) is key to advancing metal-air batteries and regenerative fuel cells. In this study, nitrogen-doped binary metal (Mn and Ni) oxides (N-BMOs) and Pt-decorated N-BMOs were synthesised using three methods and tested as ORR and OER catalysts in alkaline media. Their physicochemical properties were characterised by XRD, N-sorption, TEM, and XPS, while their electrochemical performance was evaluated using voltammetry and impedance spectroscopy.

View Article and Find Full Text PDF

Aims: To determine whether adults with type 2 diabetes (T2D) treated with retatrutide report greater changes in self-reported appetite, dietary restraint, and disinhibition compared to placebo or dulaglutide and to examine associations with weight change.

Materials And Methods: These pre-specified exploratory analyses examined changes from baseline in Appetite Visual Analogue Scale (VAS) and Eating Inventory (EI) scores after 24 and 36 weeks of once-weekly treatment with placebo, dulaglutide 1.5 mg, or retatrutide 0.

View Article and Find Full Text PDF

The current guidelines for cardiovascular disease prevention by the European Society of Cardiology highlight the undisputable benefits of exercise and a physically active lifestyle for cardiovascular risk reduction. In addition to the health benefits of physical activity, observational data suggests that regular physical activity lowers all-cause mortality. However, this was not confirmed by Mendelian randomization studies and randomized controlled trials.

View Article and Find Full Text PDF